Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 22


Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies.

Raftopoulos H, Laadem A, Hesketh PJ, Goldschmidt J, Gabrail N, Osborne C, Ali M, Sherman ML, Wang D, Glaspy JA, Puccio-Pick M, Zou J, Crawford J.

Support Care Cancer. 2015 Sep 14. [Epub ahead of print]


Endothelial ALK1 Is a Therapeutic Target to Block Metastatic Dissemination of Breast Cancer.

Cunha SI, Bocci M, Lövrot J, Eleftheriou N, Roswall P, Cordero E, Lindström L, Bartoschek M, Haller BK, Pearsall RS, Mulivor AW, Kumar R, Larsson C, Bergh J, Pietras K.

Cancer Res. 2015 Jun 15;75(12):2445-56. doi: 10.1158/0008-5472.CAN-14-3706.


Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.

Stewart R, Morrow M, Hammond SA, Mulgrew K, Marcus D, Poon E, Watkins A, Mullins S, Chodorge M, Andrews J, Bannister D, Dick E, Crawford N, Parmentier J, Alimzhanov M, Babcook JS, Foltz IN, Buchanan A, Bedian V, Wilkinson RW, McCourt M.

Cancer Immunol Res. 2015 Sep;3(9):1052-62. doi: 10.1158/2326-6066.CIR-14-0191. Epub 2015 May 5.


Inhibition of bone morphogenetic protein signal transduction prevents the medial vascular calcification associated with matrix Gla protein deficiency.

Malhotra R, Burke MF, Martyn T, Shakartzi HR, Thayer TE, O'Rourke C, Li P, Derwall M, Spagnolli E, Kolodziej SA, Hoeft K, Mayeur C, Jiramongkolchai P, Kumar R, Buys ES, Yu PB, Bloch KD, Bloch DB.

PLoS One. 2015 Jan 20;10(1):e0117098. doi: 10.1371/journal.pone.0117098. eCollection 2015.


Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia.

Suragani RN, Cawley SM, Li R, Wallner S, Alexander MJ, Mulivor AW, Gardenghi S, Rivella S, Grinberg AV, Pearsall RS, Kumar R.

Blood. 2014 Jun 19;123(25):3864-72. doi: 10.1182/blood-2013-06-511238. Epub 2014 May 2.


Differential muscle hypertrophy is associated with satellite cell numbers and Akt pathway activation following activin type IIB receptor inhibition in Mtm1 p.R69C mice.

Lawlor MW, Viola MG, Meng H, Edelstein RV, Liu F, Yan K, Luna EJ, Lerch-Gaggl A, Hoffmann RG, Pierson CR, Buj-Bello A, Lachey JL, Pearsall S, Yang L, Hillard CJ, Beggs AH.

Am J Pathol. 2014 Jun;184(6):1831-42. doi: 10.1016/j.ajpath.2014.03.003. Epub 2014 Apr 13.


A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers.

Attie KM, Allison MJ, McClure T, Boyd IE, Wilson DM, Pearsall AE, Sherman ML.

Am J Hematol. 2014 Jul;89(7):766-70. doi: 10.1002/ajh.23732. Epub 2014 Apr 26.


Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis.

Suragani RN, Cadena SM, Cawley SM, Sako D, Mitchell D, Li R, Davies MV, Alexander MJ, Devine M, Loveday KS, Underwood KW, Grinberg AV, Quisel JD, Chopra R, Pearsall RS, Seehra J, Kumar R.

Nat Med. 2014 Apr;20(4):408-14. doi: 10.1038/nm.3512. Epub 2014 Mar 23.


Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer.

Bendell JC, Gordon MS, Hurwitz HI, Jones SF, Mendelson DS, Blobe GC, Agarwal N, Condon CH, Wilson D, Pearsall AE, Yang Y, McClure T, Attie KM, Sherman ML, Sharma S.

Clin Cancer Res. 2014 Jan 15;20(2):480-9. doi: 10.1158/1078-0432.CCR-13-1840. Epub 2013 Oct 30.


Knockdown of β-catenin with dicer-substrate siRNAs reduces liver tumor burden in vivo.

Dudek H, Wong DH, Arvan R, Shah A, Wortham K, Ying B, Diwanji R, Zhou W, Holmes B, Yang H, Cyr WA, Zhou Y, Shah A, Farkiwala R, Lee M, Li Y, Rettig GR, Collingwood MA, Basu SK, Behlke MA, Brown BD.

Mol Ther. 2014 Jan;22(1):92-101. doi: 10.1038/mt.2013.233. Epub 2013 Oct 3.


Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women.

Sherman ML, Borgstein NG, Mook L, Wilson D, Yang Y, Chen N, Kumar R, Kim K, Laadem A.

J Clin Pharmacol. 2013 Nov;53(11):1121-30. doi: 10.1002/jcph.160. Epub 2013 Sep 9.


Characterization of Fc-fusion protein aggregates derived from extracellular domain disulfide bond rearrangements.

Strand J, Huang CT, Xu J.

J Pharm Sci. 2013 Feb;102(2):441-53. doi: 10.1002/jps.23421. Epub 2012 Dec 14.


A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers.

Attie KM, Borgstein NG, Yang Y, Condon CH, Wilson DM, Pearsall AE, Kumar R, Willins DA, Seehra JS, Sherman ML.

Muscle Nerve. 2013 Mar;47(3):416-23. doi: 10.1002/mus.23539. Epub 2012 Nov 21.


Specificity and structure of a high affinity activin receptor-like kinase 1 (ALK1) signaling complex.

Townson SA, Martinez-Hackert E, Greppi C, Lowden P, Sako D, Liu J, Ucran JA, Liharska K, Underwood KW, Seehra J, Kumar R, Grinberg AV.

J Biol Chem. 2012 Aug 10;287(33):27313-25. doi: 10.1074/jbc.M112.377960. Epub 2012 Jun 20.


A novel therapeutic approach to treating obesity through modulation of TGFβ signaling.

Koncarevic A, Kajimura S, Cornwall-Brady M, Andreucci A, Pullen A, Sako D, Kumar R, Grinberg AV, Liharska K, Ucran JA, Howard E, Spiegelman BM, Seehra J, Lachey J.

Endocrinology. 2012 Jul;153(7):3133-46. doi: 10.1210/en.2012-1016. Epub 2012 May 1.


Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth.

Castonguay R, Werner ED, Matthews RG, Presman E, Mulivor AW, Solban N, Sako D, Pearsall RS, Underwood KW, Seehra J, Kumar R, Grinberg AV.

J Biol Chem. 2011 Aug 26;286(34):30034-46. doi: 10.1074/jbc.M111.260133. Epub 2011 Jul 7.


A soluble activin receptor type IIb prevents the effects of androgen deprivation on body composition and bone health.

Koncarevic A, Cornwall-Brady M, Pullen A, Davies M, Sako D, Liu J, Kumar R, Tomkinson K, Baker T, Umiker B, Monnell T, Grinberg AV, Liharska K, Underwood KW, Ucran JA, Howard E, Barberio J, Spaits M, Pearsall S, Seehra J, Lachey J.

Endocrinology. 2010 Sep;151(9):4289-300. doi: 10.1210/en.2010-0134. Epub 2010 Jun 23.


Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type.

Cadena SM, Tomkinson KN, Monnell TE, Spaits MS, Kumar R, Underwood KW, Pearsall RS, Lachey JL.

J Appl Physiol (1985). 2010 Sep;109(3):635-42. doi: 10.1152/japplphysiol.00866.2009. Epub 2010 May 13.


Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb.

Sako D, Grinberg AV, Liu J, Davies MV, Castonguay R, Maniatis S, Andreucci AJ, Pobre EG, Tomkinson KN, Monnell TE, Ucran JA, Martinez-Hackert E, Pearsall RS, Underwood KW, Seehra J, Kumar R.

J Biol Chem. 2010 Jul 2;285(27):21037-48. doi: 10.1074/jbc.M110.114959. Epub 2010 Apr 12.


ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth.

Mitchell D, Pobre EG, Mulivor AW, Grinberg AV, Castonguay R, Monnell TE, Solban N, Ucran JA, Pearsall RS, Underwood KW, Seehra J, Kumar R.

Mol Cancer Ther. 2010 Feb;9(2):379-88. doi: 10.1158/1535-7163.MCT-09-0650. Epub 2010 Feb 2.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk